Table of Contents 2
List of Tables 4
List of Figures 4
MediGene AG Spshot 5
MediGene AG Overview 5
Key Facts 5
MediGene AG - Research and Development Overview 6
Key Therapeutic Areas 6
MediGene AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combition Treatment Modalities 12
MediGene AG - Pipeline Products Glance 13
MediGene AG - Late Stage Pipeline Products 13
Phase III Products/Combition Treatment Modalities 13
MediGene AG - Clinical Stage Pipeline Products 14
Phase II Products/Combition Treatment Modalities 14
Phase I Products/Combition Treatment Modalities 15
MediGene AG - Early Stage Pipeline Products 16
Preclinical Products/Combition Treatment Modalities 16
Discovery Products/Combition Treatment Modalities 17
MediGene AG - Unknown Stage Pipeline Products 18
Unknown Products/Combition Treatment Modalities 18
MediGene AG - Drug Profiles 19
Cellular Immunotherapy 1 for Oncology - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Cellular Immunotherapy 2 for Oncology - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Cellular Immunotherapy for Acute Myeloblastic Leukemia - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Cellular Immunotherapy for Multiple Myeloma - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Cellular Immunotherapy for Oncology - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Cellular Immunotherapy to Target hTERT and Survivin for Prostate Cancer - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Cellular Immunotherapy to Target MAGE-A1 for Multiple Myeloma - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Cellular Immunotherapy to Target Opa-Interacting Protein 4 and Wilm’s Tumor 1 for Acute Myeloblastic Leukemia - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
human papillomavirus [serotypes 16, 31] (virus like particle) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Monoclol Antibodies to Target TCR for Autoimmune Disease and T-Cell Leukemia - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
RhuDex - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
sinecatechins - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MediGene AG - Pipeline Alysis 34
MediGene AG - Pipeline Products by Target 34
MediGene AG - Pipeline Products by Route of Administration 35
MediGene AG - Pipeline Products by Molecule Type 36
MediGene AG - Pipeline Products by Mechanism of Action 37
MediGene AG - Dormant Projects 38
MediGene AG - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
etomoxir 39
Monoclol Antibody for Ovarian Cancer 39
MediGene AG - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42